It has signed a commercial deal with Hospital Ángeles to pilot its Steriwave nasal photodisinfection treatment at two flagship Mexican hospitals, following positive Phase 3 results.

The LANTERN trial found nasal photodisinfection cut surgical site infections by an estimated 40% when added to standard care, clearing the path toward FDA engagement.

NHS Golden Jubilee, the UK's largest hip and knee replacement centre, has added Ondine Biomedical's nasal photodisinfection therapy to its surgical infection-prevention pathway.

It has delayed the topline results by around 6 weeks, citing extra time needed to finalise the trial's database ahead of regulatory submission.

The LANTERN trial database lock is days away, with statistical analysis to follow and top-line readout expected within one to two weeks thereafter.

"Accessing brain surgery through the nose is a remarkable medical advancement, but it inherently elevates the risk of patient self-infection as many pathogens reside in the nose," said Carolyn Cross, CEO

Results from the SMURF pilot presented at the CSRT conference showed nasal photodisinfection is operationally feasible in the ICU and produced exploratory reductions in hospital‑acquired and ventilator‑associated pneumonia.

A University of Ottawa Heart Institute pilot found a statistically significant reduction in cardiac surgical-site infections after adding Ondine Biomedical’s Steriwave nasal photodisinfection to pre-surgical protocols.

Ondine Biomedical is looking forward to top-line results this spring, for pivotal LANTERN Phase 3 trial, and it is preparing to ramp up its scale.